Evidence map›Paper›PMID 27562376›Full record

ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017

Genetic Deletion of the Nociceptin/Orphanin FQ Receptor in the Rat Confers Resilience to the Development of Drug Addiction.

Marsida Kallupi, Giulia Scuppa, Giordano de Guglielmo, Girolamo Calò, Friedbert Weiss, Michael A Statnick, Linda M Rorick-Kehn, Roberto Ciccocioppo

Open access · bronzeAbstract read
In one paragraph

Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. The Downregulation of Opioid Receptors and Neuropathic Pain.International journal of molecular sciences · 2023
    Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Marsida KallupiSchool of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy.
Giulia ScuppaSchool of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy.
Giordano de GuglielmoSchool of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy.
Girolamo CalòDepartment of Medical Science, Section of Pharmacology and National Institute of Neuroscience, University of Ferrara, Ferrara, Italy.
Friedbert WeissMolecular and Cellular Neuroscience Department, The Scripps Research Institute, La Jolla, CA, USA.
Michael A StatnickLilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN USA.
Linda M Rorick-KehnLilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN USA.
Roberto CiccocioppoSchool of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy.
Scripps Research Institute · USEli Lilly (United States) · USUniversità di Camerino · ITUniversity of Ferrara · IT

Funding

The Nociceptin ORL1 System: Treatment Target for RelapseR01AA014351 · NIAAA · SCRIPPS RESEARCH INSTITUTE, THE · PI Friedbert Weiss · 2004 to 2026
$7.3M
NIAAA NIH HHS R01 AA014351
6 · The paper itself

Abstract

The nociceptin (NOP) receptor is a G-protein-coupled receptor whose natural ligand is the NOP/orphanin FQ (N/OFQ) peptide. Evidence from pharmacological studies suggests that the N/OFQ system is implicated in the regulation of several addiction-related phenomena, such as drug intake, withdrawal, and relapse. Here, to further explore the role of NOP system in addiction, we used NOP (-/-) rats to study the motivation for cocaine, heroin, and alcohol self-administration in the absence of N/OFQ function. Conditioned place preference (CPP) and saccharin (0.2% w/v) self-administration were also investigated. Results showed that NOP (-/-) rats self-administer less cocaine (0.25, 0.125, or 0.5 mg/infusion) both under a fixed ratio 1 and a progressive ratio schedule of reinforcement compared with wild-type (Wt) controls. Consistently, cocaine (10 mg/kg, i.p.) was able to induce CPP in Wt but not in NOP (-/-). When NOP (-/-) rats were tested for heroin (20 μg/infusion) and ethanol (10% v/v) self-administration, they showed significantly lower drug intake compared with Wt. Conversely, saccharin self-administration was not affected by NOP deletion, excluding the possibility of nonspecific learning deficits or generalized disruption of reward mechanisms in NOP (-/-) rats. These findings were confirmed with pharmacological experiments using two selective NOP antagonists, SB-612111 and LY2817412. Both drugs attenuated alcohol self-administration in Wt rats but not in NOP (-/-) rats. In conclusion, our results demonstrate that genetic deletion of NOP receptors confers resilience to drug abuse and support a role for NOP receptor antagonism as a potential treatment option for drug addiction.

Indexed as

AnimalsBehavior, AnimalCocaineCocaine-Related DisordersDisease Models, AnimalDopamine Uptake InhibitorsLearningNarcotic AntagonistsNociceptin ReceptorRatsRats, TransgenicRats, WistarReceptors, OpioidSelf AdministrationCocaineDopamine Uptake InhibitorsNarcotic AntagonistsNociceptin ReceptorOprl1 protein, ratReceptors, Opioid

Identifiers

PMID27562376
PMCPMC5240182
OpenAlexW2512806904

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.